Early Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy
María G. Crespo‐Leiro(Complexo Hospitalario Universitario A Coruña), Brian Drachman(Penn Presbyterian Medical Center), Diego Delgado(British Heart Foundation), Mathew S. Maurer(Alnylam Pharmaceuticals (United States)), Pablo García‐Pavía(Universidad Francisco de Vitoria), Valentina Marino(University of Chieti-Pescara), Ben Ebede(Pfizer (United States)), Ronnie Wang(Pfizer (United States)), Thibaud Damy(Inserm), Mazen Hanna(Cleveland Clinic)
Cited by 0
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k